Delayed Tolerance Through Mixed Chimerism

Kidney Failure Clinical Trial

Official title:

Delayed Tolerance Through Mixed Chimerism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05900401
• Other study ID #: 2023P000486
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2023
• Est. completion date: December 2030

Study information

• Verified date: April 2024
• Source: Massachusetts General Hospital
• Contact: Tatsuo Kawai
• Phone: 617-726-0289
• Email: tkawai[@]mgh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the safety and effectiveness of a bone marrow transplant after kidney transplant (from either a living or deceased donor). An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Description:

Recipients of previous living donor (LD) or deceased donor (DD) kidney transplants that were maintained on conventional immunosuppression (I.S.), will receive a conditioning regimen that includes rituximab on study day -6, fludarabine 15 mg/m2/day on days -5 to -3 (3 doses), Cyclophosphamide (30 mg/kg/day) on days -5 and -4, followed by local thymic irradiation (7 Gy) on day -1 and Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1. Donor hematopoetic stem cells (HSCs) will be infused on study day 0. Methylprednisolone 250mg/day will be started on day 0 and tapered off by day 20 (Fig. 2). Prophylaxis will be provided for hemorrhagic cystitis, PCP, fungal infection, CMV, and perioperative infection. All patients who require any blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at least 12 months following HSC Transplant. The recipients will undergo renal allograft biopsy at 6 months after HSCT. If the I.S. withdrawal criteria are met, I.S. will be slowly tapered off by 9-12 months

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2030
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Recipient Inclusion Criteria

1. Male or female 18-65 years of age.

2. Kidney transplant recipients from either LD or DD, with cryo-preserved HSCs available, good renal function (GFR>45 ml/min/1.73m2), normal current allograft biopsy, and no history of documented rejection episodes.

3. First or second renal transplant.

4. Use of FDA-approved methods of contraception (those with less than a 3% failure rate) by all recipients from the time that study treatment begins until 104 weeks (24 months) after renal transplantation. (For further information on FDA- approved methods of contraception, see https://www.fda.gov/media/150299/download

5. Ability to understand and provide informed consent.

6. Serologic evidence of prior exposure to EBV.

7. Negative COVID-19 test during screening and two days prior to HSC transplantation (HSCT). Deceased Donor (DD)

1. Male or female 18-70 years of age.

2. Consent to donate vertebral bones is obtained from the donor family.

3. HSCs are successfully cryopreserved and saved >2X106/kg (CD34+ cells) of the recipient.

4. Acceptable laboratory parameters (hematology in normal or near-normal range. Liver function <2 times the upper limit of normal, and normal creatinine)

5. Negative for viral infection with HbsAg, HIV, HCV, or HTLV-1

6. Negative COVID-19 test at the time of HSC procurement. Living Donor (LD)

1. Willingness to provide HSCs by leukapheresis or bone marrow aspiration.

2. Negative serologic pregnancy test for females of childbearing potential

3. Good general health as per conventional evaluation for kidney donation.

4. Acceptable laboratory parameters (hematology in normal or near normal range. Liver function <2 times the upper limit of normal, and normal creatinine)

5. Negative for viral infection with HbsAg, HIV, HCV, or HTLV-1.

6. Cardiac/pulmonary function within normal limits (CXR, ECG).

7. Ability to understand and provide informed consent.

8. Meets standard institutional criteria for PBSC collection.

9. Negative COVID-19 test during screening and two days prior to PBSC collection. Recipient Exclusion Criteria

1. ABO blood group-incompatible renal allograft.

2. Evidence of anti-HLA antibody (donor specific with an MFI >1000) as assessed by routine methodology (Luminex)

3. Previous history of biopsy proven rejection.

4. Persistent Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (<100,000/mm3).

5. Seropositivity for HIV-1, hepatitis B surface or core antigen, or hepatitis C virus (confirmed by hepatitis C virus RNA).

6. Active infection

7. Left ventricular ejection fraction < 40% as determined by TTE or clinical evidence of heart failure.

8. Forced expiratory volume FEV1 or DLCO < 50% of predicted.

9. Lactation or pregnancy.

10. History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix.

11. Underlying renal disease etiology with high risk of disease recurrence in the transplanted kidney (such as focal segmental glomerulosclerosis). Autoimmune diseases such as Lupus and Thrombotic Thrombocytopenic Purpura.

12. Enrollment in other investigational drug studies within 30 days prior to enrollment.

13. Abnormal (>2 times lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b) bilirubin, (c) coagulation studies (PT, PTT), or any patients on chronic anticoagulation therapy.

14. Allergy or sensitivity to any component of Siplizumab, fludarabine, CP, tacrolimus, MMF or rituximab.

15. Any medical condition that the investigator deems incompatible with participation in the trial. This includes a history of alcohol abuse or illicit drug use/dependence.

16. Non-insulin dependent diabetes (NIDDM) without good blood glucose control (HbA1c<7). Severe retinopathy, gastroparesis, or severe neuropathy which prevent subject's normal independent daily activities.

Related Conditions & MeSH terms

• Kidney Failure
• Kidney Transplant; Complications
• Renal Insufficiency

Intervention

Other:
• Bone Marrow Transplant
Months-Years after standard transplant, patients will undergo bone marrow transplant (either from prospective collection of stem cells from their living donor, or from bone marrow collected at the time of deceased donation)

Procedure:
• Peripheral Blood Stem Cell Collection
PBSC will be collected from the LD via leukapheresis 1-4 weeks before the scheduled HSCT. The donor will first undergo standard GCSF mobilization: GCSF (can be TBO-GCSF) dosed at 10 mcg/kg/d (rounded to nearest pre-filled syringe) administered subcutaneously daily for 5 consecutive days. On the 5th day, the donor will undergo standard large volume leukapheresis. The target yield will be 2-3 x 106 CD34+ cells / kg of actual recipient body weight. A maximum of 3 days of pheresis will be allowed. A minimum of 2 x 106 CD34+ cells / kg of actual recipient body weight will be required to proceed.

Drug:
• Fludarabine
Fludarabine 15 mg/m2/day on days -5 to -3 (3 doses)
• Cyclophosphamide
Cyclophosphamide (CP) 30 mg/kg/day on days -5 and -4
• Rituximab
Rituximab on study day -6
• Siplizumab
Siplizumab (anti-CD2 mAb) on days, -2, -1, 0 and +1.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Massachusetts General Hospital	ITB-Med LLC, Ossium Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of transient mixed chimerism		3 months
Primary	Incidence of renal allograft tolerance		2 years after immunosuppression withdrawal
Secondary	Incidence of Participant Survival		2 years after immunosuppression withdrawal
Secondary	Incidence of Graft Survival		2 years after immunosuppression withdrawal
Secondary	Incidence of Chimeric Transition Syndrome		3 months
Secondary	Incidence of Allograft Rejection	Measuring incidence of acute or chronic rejection free survival	2 years after immunosuppression withdrawal
Secondary	Incidence of DSA		2 years after immunosuppression withdrawal
Secondary	Incidence of GvHD		2 years after immunosuppression withdrawal
Secondary	Incidence of infections	Clinically significant, invasive or resistant opportunistic infection	2 years after immunosuppression withdrawal
Secondary	Incidence of thymic irradiation toxicities		2 years after immunosuppression withdrawal